Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

We evaluated the efficacy of metronomic etoposide or temozolomide administered with bevacizumab among recurrent glioblastoma (GBM) patients who progressed on prior bevacizumab therapy in a phase 2, open-label, two-arm trial. Twenty-three patients received bevacizumab (10 mg/kg) every 2 weeks with ei...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Reardon, David A., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John, Rich, Jeremy N., McLendon, Roger, Herndon, James E., Marcello, Jennifer, Threatt, Stevie, Friedman, Allan H., Vredenburgh, James J., Friedman, Henry S.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2010
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102515/
https://ncbi.nlm.nih.gov/pubmed/20853132
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0403-6
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια